Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 24, 2016 08:00 ET | Source: Achaogen Inc.

Achaogen Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., June 24, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug...
June 20, 2016 08:30 ET | Source: Achaogen Inc.

Achaogen’s Plazomicin Highlighted in Multiple Presentations at ASM Microbe 2016 Outlining Bactericidal Activity Against MDR Pathogens

SOUTH SAN FRANCISCO, Calif., June 20, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug...
June 09, 2016 08:30 ET | Source: Achaogen Inc.

Achaogen Announces Plazomicin Data Presentations at ASM Microbe 2016 Annual Meeting

SOUTH SAN FRANCISCO, Calif., June 09, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug...
June 03, 2016 08:00 ET | Source: Achaogen, Inc.

Achaogen Adds Tobin Schilke as Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., June 03, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug...
June 02, 2016 08:00 ET | Source: Achaogen, Inc.

Achaogen Awarded $20 Million Contract Option by BARDA to Support Development of Plazomicin for Multi-Drug Resistant Gram-Negative Infections

SOUTH SAN FRANCISCO, Calif., June 02, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug...
June 02, 2016 08:00 ET | Source: Achaogen, Inc.

Achaogen Raises $25 Million in Private Placement

SOUTH SAN FRANCISCO, Calif., June 02, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug...
June 02, 2016 07:55 ET | Source: Achaogen, Inc.

Achaogen Reaches 50 Percent Patient Enrollment in Phase 3 EPIC Registration Trial of Plazomicin

SOUTH SAN FRANCISCO, Calif., June 02, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug...
May 10, 2016 08:00 ET | Source: Achaogen, Inc.

Achaogen and Crystal Bioscience Enter into Collaboration and License Agreement to Identify and Develop Antibodies for Multiple Targets

SOUTH SAN FRANCISCO, Calif. and EMERYVILLE, Calif., May 10, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials...
May 05, 2016 16:05 ET | Source: Achaogen, Inc.

Achaogen Reports First Quarter 2016 Financial Results

-- Accelerated Timeline for Reporting Top-Line Results from Phase 3 EPIC Registration Clinical Trial of Plazomicin; Top-Line Data in First Quarter of 2017 and NDA Submission in Second Half of 2017...
April 22, 2016 08:30 ET | Source: Achaogen, Inc.

Achaogen Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., April 22, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug...